Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b, approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in combination with bendamustine and rituximab; it binds to CD79b on malignant B cells, delivering the cytotoxic agent monomethyl auristatin E (MMAE) to inhibit cell division and induce apoptosis.